The strategy of AhR activation by ligands such as tapinarof has a potentiation in clinical trials for AD, as it enhances the expression of skin barrier proteins such as filaggrin, loricrin, and involucrin, thereby improving barrier function and reducing inflammation [26,27]. The gene discussed is FLG; the disease is Alzheimer disease.